Application of alkannin and analogues thereof in preparation of drugs for resisting porcine reproductive and respiratory syndrome virus
By using anti-pig reproductive and respiratory syndrome virus drugs prepared by cystolin and its analogs, the problem of lack of effective anti-PRRSV drugs in the prior art was solved, and effective inhibition and survival rate of PRRSV was achieved, and new treatment and prevention programs.
Patent Information
- Application Number
- CN202411014039.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-08
AI Technical Summary
Currently, there is a lack of effective anti-pig reproductive and respiratory syndrome virus (PRRSV) vaccines and antiviral drugs. The existing vaccines are insufficient in prevention and control and treatment, and there is no direct drug for PRRSV on the market, which makes it difficult to effectively prevent and control blue ear disease .
Using cyperin and its analogues, such as deoxycyperin, acetylcyperin or β,β-dimethacrylcyperin, as active ingredients against PRRSV, combined with pharmaceutically acceptable excipients, to prepare Drugs against pig breeding and respiratory syndrome viruses, including tablets, capsules, granules and other different dosage forms, are used to prevent and treat PRRSV infection.
Cycloxin and its analogues significantly inhibit the replication of PRRSV, improve the survival rate of pigs, and have a medium-effective amount of anti-PRRSV. Its effectiveness and safety are verified through in vitro and in vivo experiments, providing new anti-PRRSV treatment and prevention methods. .
Smart Images

Figure CN118903077A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of new uses of shikonin and its analogs, and also belongs to the field of antiviral drugs, and specifically relates to the use of shikonin or its analogs in the preparation of anti-porcine reproductive and respiratory syndrome virus (PRRSV) drugs. Background Art
[0002] Porcine reproductive and respiratory syndrome (PRRS), commonly known as "blue ear disease", is clinically characterized by abortion in late pregnancy of sows, death of piglets and weaned pigs, and severe respiratory diseases in fattening pigs. Blue ear disease is caused by porcine reproductive and respiratory syndrome virus (PRRSV).
[0003] Currently, the main method for preventing PRRS is vaccination. However, since the 1980s, no ideal PRRSV vaccine has been developed. Currently, only inactivated vaccines or attenuated vaccines can be used to prevent PRRS. Among them, the performance of inactivated vaccines on pig farms is not good. Attenuated vaccines still need to be improved in terms of cross-protection ability and prevention of breakthrough infection.
[0004] At present, there is no antiviral drug directly targeting PRRSV on the market. Only in China, there are reports of purifying pig farms from blue ear disease through traditional Chinese medicine and antibiotics such as tilmicosin. Some traditional Chinese medicines can resist PRRSV, but there is no detailed pharmaceutical evaluation; antibiotics such as tilmicosin and tylosin can act on macrophages and indirectly inhibit PRRSV replication, thereby assisting in the prevention and control of blue ear disease.
[0005] Shikonin is a purple naphthoquinone natural pigment extracted from the natural plant lithospermum officinale. Its main components are shikonin and its derivatives, including shikonin, acetylshikonin, B,p'-dimethylacrylshikonin, p-hydroxyisovalerylshikonin, isovaleryl shikonin, deoxyshikonin, etc. It has anti-cancer, anti-inflammatory and antibacterial effects. It is clinically used to treat acute and chronic hepatitis and cirrhosis (ascites). It is used in dermatology and hepatology to treat flat warts and psoriasis, and is applied topically to treat burns and promote wound healing. Eye drops are used to treat herpes simplex keratitis, and have a certain effect on epithelial dendritic keratitis and superficial parenchymal dendritic keratitis. Oil is used to treat infantile dermatitis, eczema, vaginitis, cervicitis, etc. Summary of the invention
[0006] The inventors of the present application have found that shikonin and its analogs have application prospects in resisting PRRSV. Based on this, the present invention provides the application of shikonin and its analogs in preparing drugs against porcine reproductive and respiratory syndrome virus (PRRSV).
[0007] To this end, this application discloses at least the following technical solutions:
[0008] In a first aspect, the invention discloses the use of shikonin or its analogs in the preparation of anti-porcine reproductive and respiratory syndrome virus (PRRSV) drugs, wherein the shikonin analogs are deoxyshikonin, acetylshikonin or β,β-dimethylacryloylshikonin.
[0009] Specifically, disclosed is the use of shikonin or its analogs in the preparation of a drug for preventing PRRSV infection and / or treating anti-porcine reproductive and respiratory syndrome caused by PRRSV.
[0010] According to the above scheme, the application specifically includes at least one of avoiding or reducing porcine reproductive and respiratory syndrome virus infection; inhibiting the replication of porcine reproductive and respiratory syndrome virus; and improving the survival rate of pigs infected with porcine reproductive and respiratory syndrome virus.
[0011] According to the above scheme, the PRRSV includes PRRSV-1 and PRRSV-2 types, and their subtypes.
[0012] In a second aspect, the present invention discloses an anti-porcine reproductive and respiratory syndrome virus (PRRSV) drug, comprising an anti-PRRSV effective amount of shikonin or its analogs and pharmaceutically acceptable excipients, wherein the shikonin analogs are deoxyshikonin, acetylshikonin or β,β-dimethylacryloylshikonin.
[0013] According to the above scheme, the pharmaceutically acceptable excipient is selected from one or more of solvents, dispersants, diluents, fillers, wetting agents, binders, disintegrants, lubricants, preservatives, suspending agents, emulsifiers, excipients, flavoring agents and carriers. In some embodiments, the dosage form of the composition includes tablets, capsules, granules, pills, liquid preparations, decoctions, suppositories, gels, aerosols or patches.
[0014] In a third aspect, the present invention also discloses a composition for resisting porcine reproductive and respiratory syndrome virus (PRRSV), which comprises an active ingredient of shikonin or its analogs and other anti-PRRSV components, wherein the other anti-PRRSV components include but are not limited to one of the following components: antiviral drugs (amantadine, rimantadine, baloxavir, ribavirin, interferon, arbidol, remdesivir); antibiotics (tylosin, tilmicosin, etc.), and Chinese herbal extracts with anti-PRRSV effects such as extracts of astragalus, codonopsis, atractylodes, poria, anemarrhena, etc.
[0015] In some embodiments, shikonin and its analogs can be prepared from plants of the Boraginaceae family, including but not limited to lithospermum officinale, ...
[0016] The term "anti" in the present invention means interfering with the infection process of PRRSV; inhibiting the growth of PRRSV; inhibiting the replication of PRRSV; and improving the survival rate of pigs infected with PRRSV. The term "pharmaceutically acceptable excipient" refers to a component that does not interfere with the efficacy of the biological activity of the compound and is not significantly toxic to the body at the therapeutically effective concentration of its administration, including any one or a combination of at least two of solvents, dispersants, diluents, fillers, wetting agents, adhesives, disintegrants, lubricants, preservatives, suspending agents, emulsifiers, excipients, flavoring agents, etc. and carriers. It is well known in the art to use the aforementioned components for pharmaceutically active substances. For example, the solvent includes but is not limited to water, methanol, dimethyl sulfoxide (DMSO), and the carrier includes but is not limited to: polyethylene glycol, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, gypsum powder, sucrose, cyclodextrin, amylose, magnesium stearate, pectin, gum arabic, stearic acid or cellulose lower alkyl ether. Each component can be used alone or in combination with multiple components.
[0017] The terms "effective amount" and "therapeutically effective amount" refer to the amount of a compound, agent, preparation or composition sufficient to relieve one or more symptoms of the disease or condition being treated to some extent after administration, and its intended goal can be the reduction and / or relief of symptoms or causes, or any other desired changes in the body. For example, a therapeutically effective amount is the amount of a composition comprising a compound disclosed herein required to provide a significant symptom relief effect clinically, and techniques such as dose escalation tests can be used to determine the effective amount suitable for any individual case. The therapeutically effective amount will vary depending on the activity of the compound, the condition caused by the viral infection and its severity, and the size and health of the individual to be treated. Exemplarily, the therapeutically effective amount in a mouse model can be 1 mg / kg-150 mg / kg, preferably 1 mg / kg-100 mg / kg, and more preferably, 5 mg / kg-30 mg / kg, such as 10 mg / kg or 20 mg / kg, 2 times / day.
[0018] The term "treatment" and its analogous words encompass any therapy for humans or animals other than humans, and the treatment can be for existing conditions, or can be preventive (preventive treatment), which includes curative, alleviating or preventive effects. Treatment can also include curing, alleviating or preventing symptoms associated with the disease rather than acting on the underlying cause of the disease. The term "prevention" and its analogous words include reducing the likelihood of the patient's disease or condition occurring or worsening, such as during the medication period after exposure to the PRRSV environment when influenza virus infection has not yet occurred, and treatment can be for the treatment of primary infection or infection after latent virus activation.
[0019] The composition provided in the present application can be adapted to any form of administration for the prevention and / or treatment of anti-PRRSV, including but not limited to oral, nasal, transdermal, intravenous and enteral administration, preferably by oral administration. Those skilled in the art can select a suitable formulation according to the administration method, for example, when used for oral administration, it can be made into a conventional solid preparation and liquid preparation. In some specific embodiments, the dosage form includes but is not limited to: tablets, capsules, granules, pills, liquid preparations, decoctions, suppositories, gels, aerosols or patches, etc.
[0020] The anti-porcine reproductive and respiratory syndrome virus (PRRSV) drug provided in the present application can be in a single dose or multiple dose form. Optionally, the final concentration of the shikonin and its analogs in the composition is 0.01 μM-200 μM. This concentration refers to the final concentration of shikonin and its analogs in the liquid preparation drug. The amount of shikonin and its analogs taken during treatment is adjusted according to the final concentration, dosage form and individual to be treated to ensure that the therapeutically effective amount is reached. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 is the cell survival rate of Marc-145 cells under different shikonin concentrations;
[0022] Figure 2 is the inhibition rate of PRRSV at different shikonin concentrations;
[0023] Figure 3 These are the antiviral test results of the serum of treated animals in Example 3. DETAILED DESCRIPTION
[0024] In order to make the purpose, technical scheme and advantages of the present application clearer, the present application is further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described herein are only used to explain the present application and are not intended to limit the present application. The reagents not described separately in detail in the present application are all conventional reagents and can be obtained from commercial channels; the methods not specifically described in detail are all conventional experimental methods and can be obtained from the prior art.
[0025] Porcine reproductive and respiratory syndrome (PRRS), commonly known as "blue ear disease", is caused by porcine reproductive and respiratory syndrome virus (PRRSV). Clinical symptoms include premature birth or abortion in late pregnancy in sows, mass mortality of piglets and weaned pigs, and severe respiratory diseases in fattening pigs.
[0026] PRRSV is a positive-sense single-stranded RNA virus that mutates rapidly and has evolved into multiple strains. At present, the main epidemic strains are NADC34-like strains, NADC30-like and HP-PRRSV, and the three have undergone complex recombination. Among them, the highly pathogenic blue ear virus strain (HP-PRRSV) causes serious harm to piglets and sows, with a mortality rate of more than 35%. The NADC30 strain was discovered in the United States in 2008. It broke out in vaccinated pig herds and caused the death of 30-50% of pigs. The NADC34 strain has caused a severe abortion "storm" in sow herds and increased piglet mortality in the United States. In summary, PRRSV is difficult to prevent and control and has a high mortality rate. It causes significant economic losses to pork production.
[0027] At present, the drug evaluation models for treating PRRSV are mainly divided into in vitro models and in vivo models. In vitro models mainly use various PRRSV susceptible cell lines or PRRSV pathology-related cell lines to evaluate drugs. Its advantages are that it can provide a large number of cells with the same genetic traits, is easy to operate and can eliminate the influence of other external factors, and can detect drug toxicity, effective concentration and selection index, providing more basis for later mechanism research. In vivo models generally use pigs, and various phenotypic indicators after drug treatment are used to measure the overall effect of drugs in living animals. Its advantage is that the effect of candidate drugs in vivo can be truly and systematically evaluated.
[0028] The applicant has discovered that shikonin and its analogs have anti-PRRSV activity, including PRRSV-1 and PRRSV-2, and their subtypes. The present invention specifically uses PRRSV-2, and more specifically, HP-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus (WUH3)) to perform an exemplary analysis of the experimental results.
[0029] Example 1: Test Materials
[0030] Marc-145 cells: stored in the laboratory;
[0031] Virus strain: Porcine reproductive and respiratory syndrome virus (WUH3) (belonging to (HP-PRRSV), previously preserved in the laboratory.
[0032] DMEM high-glucose medium was purchased from Sewell, fetal bovine serum (FBS) was purchased from PAN, Germany; cell activity detection kit was purchased from biosharp; Envision multifunctional microplate reader was purchased from Perkin Elmer, USA; CO2 constant temperature cell culture incubator was purchased from Jiemei.
[0033] Example 2: Shikonin Cell Level Test
[0034] (1) Cell culture
[0035] After the frozen Marc-145 cells were revived and subcultured twice, they were expanded with DMEM complete medium (DMEM medium, 10% serum, penicillin 100 U / mL, streptomycin 100 μg / mL) with an inoculation density of no less than 1×10 4 cell / mL, the subculture density should not be higher than 2×10 6 cell / mL.
[0036] (2) Preparation of test solution
[0037] A DMSO solution containing 10 mM shikonin (purchased from MCE) and its analogs was prepared as a test solution.
[0038] (3) Cytotoxicity detection of shikonin
[0039] Drug-treated wells: Marc-145 cells at 1.5×10 4 Cells / well (volume 100 μL) were inoculated in a 96-well cell culture plate. When the cells adhered to the wall and the confluence rate exceeded 90%, the test solution was diluted into 9 concentration gradients with DMEM maintenance medium (DMEM medium, 2% serum, penicillin 100U / mL, streptomycin 100μg / mL), each concentration gradient was set with 6 replicates, and the final concentrations were 50μM, 25μM, 12.5μM, 6.25μM, 3.125μM, 1.563μM, 0.7813μM, 0.3906μM, 0.09766μM. After 72h of culture, the supernatant was discarded, and 100μL DMEM medium containing 10% cell counting Kit-8 reagent was added to the remaining cells. After incubation at room temperature for 120min, the OD450 reading was detected with an Envision multifunctional microplate reader and recorded as OD (drug addition).
[0040] Untreated control wells: The difference from drug-treated wells is that no test solution is added, and its OD450 reading is recorded as OD (0 drug addition).
[0041] Blank control well: The difference from the drug-treated well is that it does not contain cells and no test solution is added. Its OD450 reading is recorded as OD (blank).
[0042] Calculate cell survival rate (%) = [OD (drug added) - OD (blank)] / [OD (0 drug added) - OD (blank)] × 100%
[0043] like Figure 1 As shown, Marc-145 cells were treated with shikonin at the highest concentration of 50 μM and then diluted 2-fold in sequence, for a total of 9 dilutions. When treated with 6.25 μM for 72 hours, the cells showed weak toxicity. When treated with 3.125 μM for 72 hours, the cell viability was no different from that of the control group, indicating that shikonin was not toxic to cells at this concentration. 50 The value is 9.956 μM.
[0044] (4) In vitro antiviral activity test
[0045] Drug-treated wells: Marc-145 cells were plated at 1.5×10 4 Cells / well (volume 100 μL) were inoculated in a 96-well cell culture plate. When the cells adhered and the confluence rate exceeded 90%, they were replaced with DMEM maintenance medium (DMEM medium, 2% serum, penicillin 100U / mL, streptomycin 100μg / mL). The infection group was added with 0.1MOI (multiplicity of infection) of WUH3 porcine reproductive and respiratory syndrome virus. At the same time, the test solution was diluted with maintenance medium into 6 concentration gradients and added to each drug-treated well. Each concentration gradient had 3 replicates, and the final concentrations were 2μM, 1μM, 0.5μM, 0.25μM, 0.1μM, and 0.01μM, respectively. Cultured in a 37°C cell culture incubator for 60h. Take out the culture plate and freeze and thaw once at -20°C, blow each well and draw 180μL to add to the virus nucleic acid purification kit machine to automatically extract RNA.
[0046] The reverse transcription kit (RT101-01, Nanjing Novozymes) and SYBR Green dye (Q311-02-AA, Nanjing Novozymes) were used for the operation, and the CT value of each well was determined by using a Heal Force real-time fluorescence quantitative PCR instrument.
[0047] Virus control wells: The difference from the drug-treated wells is that no test solution is added.
[0048] Calculate the number of drug-virus replication copies in each test well. Plasmid copy number C (copies / μL) = plasmid mass concentration (ng / μL) × 10 -9 ×6.02×10 23 / plasmid base number / 660 = plasmid concentration (ng / μl) × 6.02 × 10 14 / plasmid base number / 660 = 2.08 × 10 10After gradient dilution of the plasmid, fluorescence quantitative amplification was performed to obtain the standard curve: y = -3.0861x + 34.648 (R 2 =0.9959), x is the lg template copy number, y is the Ct value;
[0049] Virus inhibition rate (%) = (virus copy number in virus control group - virus copy number in drug administration group) / virus copy number in virus control group × 100%
[0050] The results are as follows Figure 2 As shown in Figure 2, shikonin can significantly inhibit viral genome replication in a dose-dependent manner, with a median effective concentration of IC 50 44.6nM respectively.
[0051] The drug selection index (SI) is used to determine the safe range of drug effects. A drug selection index greater than 1 is considered effective, and the larger the index, the larger the safe range. The calculation formula is: SI = CC 50 / EC 50 Combined with the above results, the selection index of shikonin against porcine reproductive and respiratory syndrome virus on Marc-145 was 222.93, which was much greater than 1. This shows that shikonin has the effect of resisting porcine reproductive and respiratory syndrome virus WUH3 strain.
[0052] Example 3: Antiviral testing of serum from treated animals
[0053] Mice were intragastrically administered, dose: 30 mg / kg;
[0054] Drug-treated wells: Marc-145 cells were plated at 1.5×10 4 Cells / well (volume 100 μL) were inoculated in a 96-well cell culture plate. When the cells adhered and the confluence rate exceeded 90%, they were replaced with DMEM maintenance medium (DMEM medium, 2% serum, penicillin 100U / mL, streptomycin 100μg / mL). 0.1MOI (multiplicity of infection) of WUH3 porcine reproductive and respiratory syndrome virus was added to the infection group. At the same time, serum samples at different time points (blank serum 0h before administration, 0.5h after gavage, 2h after gavage) after the test sample was gavaged into mice were diluted with DMEM maintenance medium to form 3 concentration gradients, with final concentrations of 10%, 5%, and 1%, respectively. Cultured in a 37°C cell culture incubator for 48h. The rest of the operations were the same as the in vitro antiviral activity test steps.
[0055] The results are as follows Figure 3As shown in the figure, compared with the serum before administration, the high, medium and low concentration serum after administration can inhibit viral replication in a dose-dependent manner, indicating that shikonin can be orally absorbed by animals. The blank serum before administration has the effect of inhibiting viral replication, which may be because the cytokines in the serum have a broad-spectrum inhibitory effect on viral replication at high concentrations, but this effect disappears with dilution, while shikonin still has a good inhibitory effect at low concentrations, which is consistent with the in vitro antiviral experimental data.
[0056] Example 4
[0057] The inhibitory activities of acetylshikonin, β,β-dimethylacryloylshikonin and deoxyshikonin against PRRSV in Marc-145 cells are shown in Table 1.
[0058] Table 1. Inhibitory activity of acetylshikonin, β,β-dimethylacryloylshikonin and deoxyshikonin on PRRSV in Marc-145 cells (5 μM)
[0059] Compound Inhibition rate (5μM) Acetylshikonin 99% β,β-Dimethylacryloylshikonin 99% Deoxyshikonin 99%
Claims
1. Use of shikonin or its analogs in the preparation of anti-porcine reproductive and respiratory syndrome virus (PRRSV) drugs, wherein the shikonin analogs are deoxyshikonin, acetylshikonin or β,β-dimethylacryloylshikonin.
2. The use according to claim 1, characterized in that: The application is the application of shikonin or its analogs in the preparation of medicines for preventing PRRSV infection and / or treating anti-porcine reproductive and respiratory syndrome caused by PRRSV.
3. The use according to claim 1, characterized in that: The application comprises at least one of avoiding or reducing the infection of porcine reproductive and respiratory syndrome virus; inhibiting the replication of porcine reproductive and respiratory syndrome virus; and improving the survival rate of pigs infected with porcine reproductive and respiratory syndrome virus.
4. The use according to claim 1, characterized in that: The shikonin and its analogs are prepared from plants of Boraginaceae.
5. The use according to claim 4, characterized in that: The Boraginaceae plant is selected from Lithospermum officinale, ... parviflorum or Lithospermum officinale.
6. An anti-porcine reproductive and respiratory syndrome virus (PRRSV) drug, comprising an anti-PRRSV effective amount of shikonin or its analogues and pharmaceutically acceptable excipients, wherein the shikonin analogue is deoxyshikonin, acetylshikonin or β,β-dimethylacryloylshikonin.
7. The drug according to claim 6, characterized in that: The pharmaceutically acceptable excipient is selected from one or more of solvents, dispersants, diluents, fillers, wetting agents, binders, disintegrants, lubricants, preservatives, suspending agents, emulsifiers, excipients, flavoring agents and carriers.
8. The drug according to claim 6, characterized in that: The dosage forms of the drug include tablets, capsules, granules, pills, liquid preparations, decoctions, suppositories, gels, aerosols or patches.
9. A composition for resisting PRRSV, characterized in that: The invention comprises shikonin or its analogue active component and other anti-PRRSV components, wherein the other anti-PRRSV components are selected from antiviral drugs, antibiotics or traditional Chinese medicine extracts having anti-PRRSV effects.
10. The composition according to claim 9, characterized in that: The antiviral drug is selected from amantadine, rimantadine, baloxavir, ribavirin, interferon, arbidol or remdesivir, the antibiotic is selected from tylosin or tilmicosin, and the Chinese medicine extract with anti-PRRSV activity is selected from Chinese medicine extracts of astragalus, codonopsis, atractylodes, poria and anemarrhena.
